Peptides: Good or Bad? An Honest Look at Pros and Cons

Key Takeaways

• Safety context: Safety data for peptides ranges from extensive Phase 3 trial data (GLP-1 receptor agonists, tesamorelin, teriparatide) to large international observational datasets for compounds not FDA-approved in the US (thymosin alpha-1) to animal-only preclinical data (BPC-157, TB-500), with evidence quality varying enormously across the class.
• Primary benefits: FDA-approved peptide drugs demonstrate meaningful clinical benefits across metabolic disease, body composition, bone density, and cardiovascular risk in large controlled trials.
• Primary risks: GLP-1 agonists produce significant GI adverse effects in a large proportion of users; GH secretagogues carry glucose and IGF-1 monitoring requirements; research-use-only peptides from unregulated sources carry contamination and unknown safety risks.
• Evidence quality summary: The clinical record for approved peptide drugs spans decades of post-market data; the record for most research-use-only peptides spans rodent studies and self-reports. These evidence categories should not be treated interchangeably.

Why the Question "Are Peptides Good or Bad?" Requires More Than One Answer

Peptides are one of the most pharmacologically diverse compound categories in medicine. Muttenthaler and colleagues, in a 2021 comprehensive review in Nature Reviews Drug Discovery, characterized the class by its high target selectivity, relative metabolic safety, and growing clinical footprint — noting that these properties have driven decades of drug development. Fosgerau and Hoffmann, in a 2015 review in Drug Discovery Today, explained that peptides metabolize to amino acids, a structural property that is one factor in the tolerability profiles observed in certain approved peptide drugs. But these general class properties apply most directly to pharmaceutically characterized compounds — not to every product marketed as a peptide. The evidence quality for each claim below is graded throughout: [Human RCT] / [Human observational] / [Animal data] / [Anecdotal/case report].

The Case for Peptides: What the Evidence Shows

The benefits documented in the peptide literature span multiple classes and multiple clinical outcomes. The strongest evidence exists for FDA-approved compounds; more limited but clinically relevant evidence exists for several compounded and investigational compounds.

Metabolic and weight management benefits: GLP-1 agonists

GLP-1 receptor agonists represent the strongest pro argument for peptides as a drug class. Chandarana and colleagues, in a 2024 review in Current Drug Research Reviews, documented broad clinical benefits of peptide drugs across HIV, multiple sclerosis, osteoporosis, diabetes, and cancer. For GLP-1 agents specifically: in the STEP 1 trial by Wilding and colleagues, published in the New England Journal of Medicine in 2021, once-weekly semaglutide 2.4 mg produced a mean weight loss of 14.9% over 68 weeks versus 2.4% for placebo — among the most significant pharmacological weight-management effects ever documented. Falutz and colleagues, in a 2010 study in the Journal of Acquired Immune Deficiency Syndromes, demonstrated approximately 18% visceral fat reduction with tesamorelin alongside improved body image distress, without significant glucose perturbation in the HIV lipodystrophy population. These are not marginal effects — they represent clinically meaningful outcomes from controlled trials. [Human RCT]

Body composition benefits: GH secretagogues

Growth hormone secretagogues — including ipamorelin, CJC-1295, and sermorelin — are studied for body composition effects through GH-IGF-1 axis stimulation. Sigalos and Pastuszak, in a 2018 review in Sexual Medicine Reviews, described the class as generally tolerated in the Phase 1–2 literature, with investigational signals reported for body composition, bone density, and sleep. These are not Phase 3 efficacy findings, and this is a narrative review rather than a systematic review or controlled trial. Raun and colleagues' 1998 foundational characterization of ipamorelin in the European Journal of Endocrinology demonstrated selectivity for GH release without cortisol or prolactin effects — a pharmacological distinction from less selective GH-axis compounds. The evidence base for GH secretagogues is smaller than for GLP-1 agents; Phase 1–2 trial data provide investigational context, not Phase 3 efficacy. [Human observational / Human RCT — Phase 1–2]

Immune function: thymosin alpha-1

Thymosin alpha-1 is among the most studied investigational peptides in terms of human safety and immune function. Dinetz and Lee, in a 2024 narrative review in Alternative Therapies in Health and Medicine, analyzed thymosin alpha-1 across more than 11,000 subjects and reported no significant adverse effects in the analyzed cohort. Thymosin alpha-1 is not FDA-approved in the US for any indication; it has marketing authorization in approximately 35 countries outside the US (as Zadaxin/thymalfasin) for indications including hepatitis B. FDA has classified thymosin alpha-1 as a Category 2 bulk drug substance and does not intend to exercise enforcement discretion for its compounding under § 503A. [Human observational from large dataset]

Target selectivity: structural advantage of the class

The general pharmacological advantage of peptides as a class is their high selectivity. Because peptides bind specific receptors through sequence-dependent molecular recognition, off-target effects are structurally less likely than with many small-molecule drugs that interact with multiple receptor types. Lau and Dunn, writing in Bioorganic and Medicinal Chemistry in 2018, catalogued more than 60 FDA-approved peptide drugs and 150 in clinical development, characterizing the therapeutic spectrum and noting selectivity as a class property that drives clinical interest. Yang and colleagues, in a 2025 review in Chinese Journal of Natural Medicines, documented the growth of approved and clinical-stage peptide therapeutics, noting improved delivery strategies addressing historical limitations. [Pharmacological characterization — established principle]

The Case Against Peptides: What the Evidence Shows

The cons documented in the peptide literature are real — and they vary significantly by compound class. Honest evaluation requires weighing documented adverse effects, evidence gaps, and sourcing risks against the benefit claims.

GLP-1 agonists: GI adverse effects

The most common and clinically significant adverse effects of GLP-1 receptor agonists are gastrointestinal: nausea, vomiting, diarrhea, and constipation. Sun and colleagues, in a 2015 network meta-analysis in Diabetes Technology & Therapeutics, quantified GLP-1 receptor agonists as significantly increasing GI adverse events versus placebo. Nausea has been reported in a substantial proportion of participants across GLP-1 receptor agonist trials, most prominently during dose initiation. Gorgojo-Martínez and colleagues, in a 2023 expert consensus review in the Journal of Clinical Medicine, addressed the management of GI adverse events with GLP-1 agonists, confirming these as common and requiring active management. Frequency: Very common (greater than 10%) for nausea during initiation; decreases with dose stabilization in most patients. [Human RCT]

GH secretagogues: glucose, fluid retention, and cancer theory

GH secretagogues carry real documented risks at supraphysiological doses. Liu and colleagues, in a landmark 2007 systematic review in the Annals of Internal Medicine, found that GH therapy in healthy elderly individuals produced small body-composition benefits but significantly more adverse events than placebo, including edema, joint pain, carpal tunnel syndrome, and glucose intolerance — the definitive "cons" citation for GH-axis interventions in non-deficient populations. Yuen and colleagues, in a 2002 review in Treatments in Endocrinology, documented GH therapy and insulin resistance. Moller and Jorgensen, in a 2009 review in Hormone Research, characterized the fluid retention mechanism. Werner and colleagues, in a 2020 review in Molecular and Cellular Endocrinology, reviewed the GH-IGF-1 axis and cancer progression — supraphysiological IGF-1 carries a theoretical cancer proliferation signal requiring monitoring, not a confirmed clinical finding at therapeutic doses. Deodati and colleagues, in a 2014 systematic review in Growth Hormone & IGF Research, found GH therapy not linked to excess cancer or cardiovascular mortality in supervised use — providing an important balancing data point to the cancer concern. [Human RCT for adverse events; Human observational for long-term cancer signal]

Evidence gaps for research-use-only peptides

The most significant con in the broader peptide landscape is not a specific adverse effect — it is the absence of evidence. Mendias and Awan, in a 2026 review in Sports Medicine, explicitly evaluated approved and unapproved peptide therapies for musculoskeletal injuries, concluding that unapproved peptides marketed direct-to-patient show favorable preclinical data but "rigorous human safety data are scarce, and there is potential for serious harm." McGuire and colleagues, in a 2025 review in Current Reviews in Musculoskeletal Medicine, specifically framed BPC-157 under the heading "Regeneration or Risk?" — acknowledging broad preclinical benefits while explicitly flagging the unknown safety concern. A 2025 pilot report by Sikiric and colleagues in Biomedicines described IV BPC-157 in 2 healthy adults with no adverse effects observed; this case-series scale does not constitute efficacy or safety evidence. As of February 2026, BPC-157 is on restricted compounding status and is not eligible for § 503A compounding; the only FDA-sanctioned pathway for human administration of BPC-157 in the United States is an IND-authorized clinical investigation under 21 CFR Part 312. [Animal data / Anecdotal/case report for most RUO compounds]

Contamination and sourcing risk

Peptides sold through online vendors as "research use only" or "not for human use" are not regulated by the FDA for quality, purity, or potency. Side effects reported from these products may be caused by the compound, by contaminants, by incorrect dosing, or by misidentified ingredients. Colalto, in a 2024 review in Regulatory Toxicology and Pharmacology addressed quality and safety assessment for peptide therapeutics, noting that quality-controlled pharmaceutical-grade peptides differ meaningfully from uncharacterized research compounds. There is no way to distinguish these causes without pharmaceutical-grade sourcing and controlled conditions. Gudeman and colleagues, in a 2013 review in Drugs in R&D, characterized pharmacy compounding risks including contamination and subpotency that apply to any compound prepared outside regulated manufacturing standards. [Human observational]

Products labeled "Research Use Only" or "Not for Human Consumption" are not approved or cleared by FDA for any human medical use. Purchasing or using such products for human therapy is not sanctioned under any regulatory pathway; FDA's intended-use doctrine (21 CFR 201.128) also applies to vendors whose marketing, packaging, or conduct signals a therapeutic intended use. This article does not endorse the use of RUO-labeled peptides for any human purpose.

Immunogenicity: a long-term unknown

Any peptide drug has the potential to trigger anti-drug antibody formation with repeated dosing — this is a general property of biological therapeutics. Achilleos and colleagues, in a 2025 review in Journal of Peptide Science, characterized immunogenicity of peptide therapeutics as a potential long-term risk requiring post-market surveillance. The clinical significance varies by compound: some anti-drug antibodies neutralize the therapeutic effect without other consequences; others may produce hypersensitivity reactions. Colalto's 2024 review also flagged that impurities and degradation products in non-pharmaceutical-grade peptides may contribute to immunogenic reactions that are not anticipated from the parent compound's characterization. [Human observational — post-market pharmacovigilance data]

A Balanced Summary: Pros and Cons by Compound Class

• FDA-approved peptide drugs (insulin, GLP-1 agonists, tesamorelin, teriparatide, abaloparatide)
  • Pros: Defined safety profiles from Phase 3 trials; demonstrated clinical efficacy for specific indications; pharmacovigilance data from post-market surveillance; regulated manufacturing quality. [Human RCT]
  • Cons: GI adverse effects for GLP-1 agents (nausea very common, greater than 10%); GH-axis adverse effects (fluid retention, glucose elevation at supraphysiological doses); compound-specific risks documented in prescribing information; injection-site reactions with injectable formulations. [Human RCT]
• Investigational or internationally-approved peptides (thymosin alpha-1)
  • Pros: Large observational safety dataset (Dinetz & Lee 2024, n > 11,000) from international clinical use; immune-modulation data from non-US clinical experience. [Human observational — international]
  • Cons: Not FDA-approved in the US for any indication; FDA has classified thymosin alpha-1 as a Category 2 bulk drug substance and does not intend to exercise enforcement discretion for its compounding under § 503A. (Regulatory note)
• Peptides sometimes prepared by compounding pharmacies (ipamorelin, CJC-1295, sermorelin)
  • Pros: Phase 1–2 clinical data reported; tolerability described in narrative reviews; GH specificity without cortisol or prolactin effects (ipamorelin); investigational signals for body composition and sleep. [Human observational / Phase 1–2]
  • Cons: FDA has classified ipamorelin and CJC-1295 as Category 2 bulk drug substances, and the agency does not intend to exercise enforcement discretion for their compounding under § 503A. Sermorelin's compounding status is historically more ambiguous due to its prior FDA-approved status, but FDA has not formally included it on the § 503A bulks list. Some compounding pharmacies prepare these compounds, but this is not a sanctioned 503A pathway for ipamorelin or CJC-1295. No Phase 3 efficacy data; glucose and IGF-1 monitoring clinically appropriate; cancer signal is theoretical but requires IGF-1 monitoring; long-term safety data limited. [Human observational / Regulatory]
• Unapproved peptides marketed as research-use-only (BPC-157, TB-500)
  • Preclinical signals: Animal data exist for tissue-repair signals with some compounds; these data do not establish human efficacy or safety and are not a basis for human use. [Animal data]
  • Cons: No Phase 3 human efficacy or safety data; contamination risk from unregulated manufacturing; no dosing validation from human pharmacokinetic studies. As of April 2026, FDA's current position is that BPC-157 and TB-500 are not eligible for compounding under § 503A (status subject to ongoing FDA rulemaking; confirm current status before prescribing). There is currently no FDA-sanctioned pathway for human therapeutic use of BPC-157 or TB-500 in the United States; they are accessible only through clinical research protocols. Evidence base insufficient to characterize risk-benefit ratio. [Animal data / Insufficient human data / Regulatory]

Contraindications: Who Should Be Particularly Cautious

The following groups face elevated risk with specific peptide categories based on pharmacological mechanism and available clinical data. For any specific compound, consult that compound's prescribing information or a qualified healthcare provider.

• Individuals with active or suspected malignancy: GH secretagogues stimulate IGF-1; elevated IGF-1 carries a theoretical cancer proliferation concern. This is not an established clinical finding at therapeutic doses, but current guidelines do not support use in individuals with active cancer. [Human observational / theoretical]
• Individuals with type 2 diabetes or insulin resistance: GH secretagogues reduce insulin sensitivity in a dose-dependent manner. Baseline and periodic glucose monitoring is standard clinical practice. [Human observational]
• Individuals with a history of pancreatitis: GLP-1 agonists are associated with pancreatitis as a rare adverse event in clinical trials and post-marketing surveillance, and it is listed as a warning in product labeling for this class. [Human RCT]
• Pregnant individuals: No adequate human safety data exists for any therapeutic peptide in pregnancy with the exception of insulin. Benefit-risk assessment must involve a provider with obstetric and prescribing expertise. [Insufficient data]
• Individuals trying to conceive: No preconception safety data exists for most therapeutic peptides discussed in this article. For couples actively trying to conceive, a provider with reproductive-medicine expertise should weigh in before peptide initiation. [Insufficient data]
• Individuals using unregulated sources: Product contamination, incorrect labeling, and dose inconsistency compound all other risks. Without pharmaceutical-grade sourcing, risk assessment is not possible. [Human observational]

Drug Interactions Worth Knowing

Drug interaction data for peptides varies by compound class and regulatory status. FDA-approved peptides have formal interaction data in their prescribing information. For research-use-only compounds, theoretical interactions are based on proposed mechanism of action.

GLP-1 receptor agonists

• Insulin and sulfonylureas: Additive hypoglycemia risk; concomitant use requires provider monitoring and potential dose adjustment of the other agent. [Human RCT — prescribing information]
• Oral medications: GLP-1 receptor agonists slow gastric emptying, which may reduce or delay absorption of orally administered medications. Relevant for narrow therapeutic index drugs. [Human observational — prescribing information]

GH secretagogues

• Glucocorticoids: Suppress GH secretion, reducing secretagogue effectiveness. [Human observational — pharmacological mechanism]
• Insulin and antidiabetic agents: GH secretagogues increase fasting glucose; dose adjustment of concurrent antidiabetics may be required. [Human observational]

This is not an exhaustive interaction list for any compound. Before starting any peptide therapy, provide your healthcare provider with a complete list of all medications, supplements, and over-the-counter products you use.

When to Seek Medical Attention

Not every side effect from a peptide requires emergency care. The following triage distinguishes symptoms that need immediate emergency attention from those warranting provider contact within 24–48 hours from those that are expected.

Seek immediate emergency care

• Signs of anaphylaxis: throat swelling, widespread hives, difficulty breathing, sudden blood pressure drop, loss of consciousness. Call 911.
• Severe abdominal pain in GLP-1 agonist users — pancreatitis is listed as a warning in product labeling for this class; possible pancreatitis requires evaluation.
• Signs of injection site infection: spreading redness, fever, purulent discharge.

Contact your provider within 24–48 hours

• Nausea or vomiting lasting more than 48 hours after GLP-1 agonist initiation or dose increase — warrants provider evaluation for dehydration. [Human RCT]
• New joint pain, edema, or carpal tunnel symptoms during GH secretagogue use — may indicate elevated IGF-1. [Human observational]
• Elevated blood glucose symptoms (increased thirst, frequent urination, fatigue) in GH secretagogue users with metabolic risk. [Human observational]
• Any symptom that prompted self-modification of dosing — always discuss with your provider.

Expected effects — monitor but not urgent

• Mild injection site redness or tenderness resolving within 24–72 hours — the most common injectable peptide side effect. Does not require intervention unless worsening.
• Mild nausea during the first 1–2 weeks of GLP-1 agonist initiation — expected during dose escalation. [Human RCT]
• Mild water retention in early GH secretagogue use — dose-dependent, typically self-resolving. [Human observational]

Which Biomarkers Can Help Monitor Safety and Benefit?

Tracking relevant biomarkers before and during any peptide use provides the objective data needed to evaluate both efficacy and adverse effects. Without baseline values, any change detected on follow-up testing cannot be confidently attributed to the compound.

• IGF-1: The primary readout of GH axis activity. Elevated IGF-1 is the earliest measurable signal of excessive GH secretagogue dosing. IGF-1 levels at baseline and during use are the most clinically important monitoring marker for this class.
• Fasting glucose and HbA1c: GH secretagogues reduce insulin sensitivity; GLP-1 agonists improve glycemic markers. A fasting glucose and HbA1c baseline characterizes metabolic status before any metabolic or GH-axis intervention.
• Fasting insulin: Complements glucose and HbA1c to characterize insulin sensitivity and resistance. A baseline fasting insulin value is particularly relevant for GLP-1 agonist use.
• Lipid panel: GLP-1 agonists improve lipid profiles; monitoring HDL cholesterol, LDL, and triglycerides provides objective benefit tracking and cardiovascular safety context.
• Liver enzymes (ALT, AST): Baseline hepatic function. Standard pre-treatment safety reference. The liver health biomarker guide covers these markers in detail.
• hs-CRP: Systemic inflammation marker. High-sensitivity CRP tracks inflammatory burden and can reflect injection site complications or unexpected inflammatory responses.
• Complete blood count (CBC): Baseline hematological reference. Standard for any injectable compound protocol.

Understanding Your Baseline

For anyone evaluating peptides — whether FDA-approved drugs with robust trial data or investigational compounds with limited evidence — knowing your baseline metabolic, hormonal, and organ function markers provides the objective reference point that makes any subsequent change interpretable. Without pre-treatment data, a rise in IGF-1, a change in fasting glucose, or a shift in lipid values cannot be attributed to the compound with any confidence. The baseline is not a formality. It is the scientific standard that distinguishes informed evaluation from empirical guesswork.

That principle is foundational to Superpower's biomarker-testing approach to preventive health. Understanding your metabolic health biomarkers before considering any intervention — peptide or otherwise — is the starting point that makes every subsequent decision more precise.

IMPORTANT SAFETY INFORMATION

This article discusses peptides as a class, including both FDA-approved medications and compounds not approved for human use. Individual peptides vary significantly in regulatory status, safety profile, and clinical evidence. Not all peptides discussed carry the same evidence base or risk profile.

Do not start, stop, or modify any peptide therapy without consulting a qualified healthcare provider who can evaluate your individual medical history, current medications, and health goals.

If you are using a peptide obtained from an unregulated source, be aware that product quality, purity, and accuracy of dosing cannot be verified without pharmaceutical-grade standards. Contaminated or mislabeled products may cause adverse effects not described in the clinical literature for the intended compound.

If you experience symptoms consistent with a serious adverse event (severe allergic reaction, chest pain, difficulty breathing, severe abdominal pain, signs of infection at an injection site), seek emergency medical care immediately.

For information about FDA-approved prescription peptides, prescribing information is available at dailymed.nlm.nih.gov. For regulatory information about specific compounds, see fda.gov.

Disclaimer: This page is provided by Superpower Health for educational and informational purposes only. This content does not constitute medical advice. Always consult a qualified healthcare provider.